REHOVOT, Israel, April 25, 2022 /PRNewswire/ — CollFactory (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ building, today announced that CEO Yehiel Tal will host the International Society for Biofabrication (ISBF) virtual event on May 2ndn/a. Mr. Tal is also a member of the ISBF Board of Directors.
The event will be organized by the ISBF Industry Relations Committee and will feature experts in the field from academia and industry: Dr. Daniel Levnerco-founder and CTO of Emulate, Dr. Ben Maoz from Tel Aviv Universitydr. Lutz Klokefounder and CSO of Cellbricks and Dr. Jeroen Eyckmans from Boston University. The Q&A session will be moderated by Ms. Katie Weimervice president of regenerative medicine at 3D systems and member of the industry relations committee of the ISBF.
Event title: Biofabrication of Microphysiological Systems for Drug Discovery and Screening – Future Prospects
Date: Monday, May 2, 2022
Weather: 10:00 a.m. EST / 4:00 p.m. CET / 11:00 PM JST
Location: Virtual event
The ISBF Industry Relations Committee mediates between university and industry and industry and industry to promote and stimulate collaboration; develop mechanisms to facilitate the translation of laboratory discoveries into manufactured products; and represent the industry in all aspects of biomanufacturing, including roadmap, technologies, cell biology, large-scale manufacturing, regulation and commercialization.
For more details and to register, please visit https://biofabricationsociety.org/
About the International Society for Biofabrication
From basic science to medical applications, the biofabrication community has come together at the International Conference on Biofabrication (Biofabrication 2019). The field of biofabrication is dedicated to the research and integration of technologies such as bio-printing, bio-tracing and bio-assembly in applications such as engineered tissue systems and regenerative medicine. The primary objective of the International Society for Biofabrication (ISBF) is to foster scientific and technological innovation and excellence for the benefit of mankind. The ISBF promotes interaction and convergence between the different disciplines in the field of Biofabrication, as well as between fundamental research and applied practice. In addition, the Society aims to promote cooperation with other organizations and scientific communities.
About Coll Plant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. The Company’s products are based on its rhCollagen (recombinant human collagen) produced with CollPlant’s proprietary plant-based genetic engineering technology. These products meet the indications of the various fields of tissue repair, aesthetics and organ manufacturing, and usher in a new era of regenerative and aesthetic medicine.
In early 2021, CollPlant entered into a global development and commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, a global leader in the dermal fillers market. Later in 2021, CollPlant entered into a strategic co-development agreement with 3D Systems for a 3D bio-printed regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.
For more information about CollPlant, visit http://www.collplant.com
Safe Harbor Statements
This press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant’s goal plans and strategies, as well as statements, other than of historical fact, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates. will or may occur in the future. These statements are often characterized by terms such as “believes”, “hopes”, “may”, “anticipates”, “should”, “intends”, “plans”, “will”, “expects”. to”, “estimates”, “projects”, “positioned”, “strategy” and similar expressions and are based on assumptions and assessments made in light of experience and management’s perception of historical trends, current conditions, expected future developments and other factors deemed appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Many factors could cause CollPlant’s actual operations or results to differ materially from the operations and results anticipated in the forward-looking statements, including, but not limited to, the following: the history of significant losses of the Company, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, if at all; the impact of the COVID-19 pandemic; the Company’s expectations regarding the timing and cost of commencing clinical trials for tissues and organs based on its rhCollagen-based BioInk and medical aesthetics products; the Company’s ability to obtain favorable preclinical and clinical trial results; regulatory actions regarding rhCollagen-based BioInk products and medical aesthetic products, including, but not limited to, the acceptance of an application for marketing authorization review and the approval of this application, and, if approved, the scope of the approved indication and labeling; the commercial success and market acceptance of the Company’s rhCollagen-based products in 3D bioprinting and medical aesthetics; the Company’s ability to establish sales and marketing capabilities or enter into agreements with third parties and its dependence on third-party distributors and resellers; the Company’s ability to establish and maintain strategic partnerships and other business collaborations; the Company’s dependence on third parties to carry out some or all aspects of the manufacture of its products; the extent of protection the Company is able to establish and maintain for intellectual property rights and the Company’s ability to conduct business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political and economic conditions in the countries in which the Company operates; capital expenditures and projected cash; changes in the Company’s strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading “Risk Factors” included in CollPlant’s most recent Annual Report on Form 20-F filed with the SEC, and in other filings by CollPlant. with the SEC. in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise forward-looking statements. , whether as a result of new information, future events or otherwise.
Contact at Coll Plant:
Deputy Managing Director & Chief Financial Officer
Tel: + 972-73-2325600
E-mail: [email protected]
Photo – https://mma.prnewswire.com/media/1803235/CollPlant_to_moderate_ISBF.jpg